Ocugen, Inc. (FRA:2H51)
Germany · Delayed Price · Currency is EUR | Market Cap | 406.82M +51.3% |
| Revenue (ttm) | 4.01M -3.6% |
| Net Income | -71.61M |
| EPS | -0.22 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 1.180 |
| Previous Close | 1.170 |
| Day's Range | 1.180 - 1.182 |
| 52-Week Range | 0.858 - 2.352 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Ocugen
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ... [Read more]
Financial Performance
In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
Ocugen to Participate in Upcoming September Investor and Industry Conferences
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen Transcript: Canaccord Genuity's 46th Annual Growth Conference
Late-stage gene therapy programs for blindness diseases are advancing, with pivotal data for RP and Stargardt expected in 2024 and potential global launches by 2028. The platform targets broad disease pathways, has strong safety data, and is supported by RMAT designation and extended financial runway.
Ocugen Earnings Call Transcript: Q2 2026
FDA cleared phase III for OCU410 in GA and granted RMAT designation; $130M financing extends cash runway into 2028. Three late-stage programs advance toward BLA filings by 2028, with top-line data for OCU400 and OCU410ST expected in H1 2027.
Ocugen Earnings release: Q2 2026
Ocugen released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Ocugen Quarterly report: Q2 2026
Ocugen has published its Q2 2026 quarterly earnings report on August 6, 2026.
Ocugen reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $1.45M, consensus $888,830. “The second quarter of 2026 marked a pivotal inflection point for Ocugen (OCGN). We closed $130 million convertible senior notes financing, extending our...
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related ...
Ocugen to Participate in Upcoming August Investor Conferences
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on July 30, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen granted RMAT designation for OCU410
Ocugen (OCGN) announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU410 for the treatment of geographic atrophy, secondary to dry age-related macular degeneration....
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...
Ocugen Proxy statement: Proxy filing
Ocugen filed a proxy statement on July 20, 2026, providing details for shareholder voting and corporate governance matters.
Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical
Ocugen (OCGN) announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International, for the exclusiv...
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 20...
Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day
Three late-stage gene therapy programs are advancing for retinitis pigmentosa, Stargardt disease, and geographic atrophy, with two BLAs planned next year and a third in 2028. Phase II/III data show strong efficacy and safety, and adaptive trial designs aim to optimize outcomes.
Ocugen to Participate in Upcoming July Industry Conferences
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th...
Ocugen Transcript: AGM 2026
The meeting, held virtually for accessibility, included director elections, ratification of the accounting firm, and advisory votes on executive compensation and its voting frequency. All proposals passed, and a brief Q&A followed with no further questions.
Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference
Gene therapy programs for retinal diseases show strong efficacy, with OCU410 reducing GA lesion growth by 31% in one year and OCU400 targeting RP across 100+ mutations. Three pivotal trials are advancing globally, with major regulatory filings and potential approvals expected by 2028.
Ocugen to Participate in Upcoming June Investor and Industry Conferences
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that th...
Ocugen price target lowered to $11 from $12 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Ocugen (OCGN) to $11 from $12 and keeps a Buy rating on the shares. The firm updated its model following…
Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum
Three late-stage gene therapy programs are advancing for major retinal diseases, using master regulator genes to address broad patient populations and unmet needs. Rolling BLA submissions and adaptive trial designs aim for regulatory filings by 2028, supported by strong cash reserves and global market strategy.
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the clos...